Open AccessIntensification of lipid-lowering therapy in patients with acute coronary syndrome
Author(s) -
Н. В. Федорова,
Д. Ю. Седых,
В. В. Кашталап,
Л. Ю. Чеснокова,
О. В. Груздева,
О. Л. Барбараш
Publication year - 2020
Publication title -
kompleksnye problemy serdečno-sosudistyh zabolevanij
Language(s) - English
Resource type - Journals
eISSN - 2587-9537
pISSN - 2306-1278
DOI - 10.17802/2306-1278-2019-8-4s-121-129
Subject(s) - acute coronary syndrome , medicine , proprotein convertase , pcsk9 , kexin , cardiology , subtilisin , risk factor , lipid profile , cholesterol , lipoprotein , intensive care medicine , ldl receptor , myocardial infarction , biochemistry , chemistry , enzyme
Lipid metabolism disorders play a key role in determining cardiovascular risk. The level of low-density lipoprotein cholesterol is a significant factor in the pathophysiology of atherosclerosis and an indicator, the assessment of which reduces the risk of cardiovascular events. The prevalence of acute coronary syndrome in Russia remains at a high level. To date, the successful implementation and implementation of standards for the management of acute coronary syndrome has significantly reduced hospital mortality rates, however, secondary prevention issues remain relevant. Despite a wide range of lipid-lowering drugs, the use of which at maximum doses in acute coronary syndrome does not allow reaching the target levels of the lipid spectrum, the risk of developing repeated cardiovascular events remains high. Recently, a promising direction is the use of type 9 subtilisin/ kexin proprotein convertase inhibitors for the intensification of lipid-lowering therapy in patients with acute coronary syndrome. This article presents the clinical case of the successful use of one of the inhibitors of the proprotein convertase of subtilisin/kexin type 9, alirocoumab, in lowering low-density lipoprotein cholesterol and thereby reducing the risk of repeated cardiovascular events in a patient with acute coronary syndrome.